November 20, 2024
Eupraxia’s DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
November 12, 2024
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
October 15, 2024
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals’ EP-104IAR for the Treatment of Knee Osteoarthritis
October 2, 2024
Eupraxia Pharmaceuticals Strengthens Senior Management Team
January 30, 2025
Director, Medical Affairs
January 30, 2025